About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Metronidazole Pharmacokinetics (PK) in Premature Infants

NCT01222585·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Michael Cohen-Wolkowiez

With

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The Emmes Company, LLC

Age

0–0

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Gestational age \<32 weeks at the time of enrollment.
Postnatal age \<91 days at the time of enrollment.
Sufficient venous access to permit administration of study medication.
Infant suspected to have a serious infection and from whom a blood culture has been obtained within 96 hours of study entry.

You may not be if

History of anaphylaxis to metronidazole or other nitroimidazole derivatives (e.g., tinidazole).
Previous exposure to metronidazole in the week prior to study.
Previous participation in the study.

The record

StatusCompleted

PhasePhase 1

Taking part24

StartedJan 2011

UpdatedFeb 6, 2014

Conditions

Serious Systemic Infections Necrotizing Enterocolitis

Where3

CHOC Children's
Orange, California, United States
Wesely Medical Center
Wichita, Kansas, United States
Duke University
Durham, North Carolina, United States

Clareo Health | Metronidazole Pharmacokinetics (PK) in Premature Infants